Personalis, Inc.·4

Jul 15, 9:27 PM ET

Chen Richard 4

4 · Personalis, Inc. · Filed Jul 15, 2026

Research Summary

AI-generated summary of this filing

Updated

Personalis (PSNL) President/CMO Richard Chen Sells 100,000 Shares

What Happened

  • Richard Chen, President and Chief Medical Officer of Personalis (PSNL), reported exercising/converting derivatives and selling stock on July 15, 2026. The filing shows an exercise/acquisition of 100,000 shares at $2.44 per share (cost $244,000) and an open-market sale of 100,000 shares at a weighted average price of $15.15 per share (proceeds $1,515,000). A separate derivative conversion of 100,000 shares is also reported with $0 exercise price (reported as a disposition of derivative shares).
  • The sale generated approximately $1.515M in proceeds; comparing the reported $2.44 exercise cost for the acquired 100,000 shares, that tranche produced roughly $1.27M in gross proceeds before taxes/fees. All optioned shares are noted as fully vested and exercisable.

Key Details

  • Transaction date: July 15, 2026
  • Sale: 100,000 shares sold at weighted avg $15.15 (range $15.01–$15.45) — proceeds $1,515,000 (F2).
  • Exercise/acquisition: 100,000 shares acquired at $2.44 each — cost $244,000 (M).
  • Additional derivative conversion: 100,000 shares reported as disposed with $0 exercise price (M).
  • Plan/authorization: Transactions effected under a Rule 10b5-1 trading plan adopted Dec 23, 2025 (F1).
  • Vesting: Shares subject to the option are fully vested and exercisable (F3).
  • Shares owned after the transactions: not disclosed in the information you provided.
  • Timeliness: Reported for the same date as the transactions (Period of Report 2026-07-15); filing appears timely.

Context

  • This filing shows an option exercise combined with an open-market sale (commonly a cashless exercise or exercise followed by sale). Because the trade was executed under a pre-established 10b5-1 plan, it was pre-scheduled rather than a necessarily discretionary, contemporaneous sale by the insider.
  • For retail investors: purchases are generally viewed as stronger bullish signals than sales. This report documents a sizable insider sale but does not, by itself, reveal the insider’s motivations (tax planning, diversification, liquidity, etc.).

Insider Transaction Report

Form 4
Period: 2026-07-15
Chen Richard
President and CMO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-07-15$2.44/sh+100,000$244,000273,880 total
  • Sale

    Common Stock

    [F1][F2]
    2026-07-15$15.15/sh100,000$1,515,000173,880 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F3]
    2026-07-15100,0000 total
    Exercise: $2.44Exp: 2027-05-24Common Stock (100,000 underlying)
Footnotes (3)
  • [F1]The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
  • [F2]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $15.01 to $15.45 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  • [F3]The shares subject to the option are fully vested and exercisable.
Signature
/s/ Aaron Tachibana, Attorney-in-Fact|2026-07-15

Documents

1 file
  • 4
    form4-07162026_010735.xmlPrimary